# Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study

> **NCT00747097** · PHASE2 · COMPLETED · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 43 (estimated)

## Conditions studied

- Time to Progression

## Interventions

- **DRUG:** gemcitabine + cetuximab

## Key facts

- **NCT ID:** NCT00747097
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2011-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00747097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00747097, "Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00747097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*